Krystal Biotech’s (KRYS) “Buy” Rating Reaffirmed at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $361.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 9.39% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Bank of America raised their price target on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Royal Bank Of Canada initiated coverage on shares of Krystal Biotech in a report on Friday, August 14th. They set an “outperform” rating and a $400.00 price target for the company. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group initiated coverage on shares of Krystal Biotech in a report on Thursday, September 24th. They set a “buy” rating and a $441.00 price target for the company. Finally, TD Cowen raised their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $377.20.

Krystal Biotech Stock Down 0.2%

Shares of KRYS traded down $0.69 during mid-day trading on Thursday, reaching $330.00. The company’s stock had a trading volume of 288,016 shares, compared to its average volume of 328,559. The business has a fifty day moving average of $340.46 and a 200 day moving average of $322.60. The company has a market cap of $9.77 billion, a price-to-earnings ratio of 41.35 and a beta of 0.50. Krystal Biotech has a 1 year low of $183.03 and a 1 year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, analysts predict that Krystal Biotech will post 7.47 earnings per share for the current year.

Insider Buying and Selling

In other Krystal Biotech news, Director Dino Rossi sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in KRYS. Terra Nova Asset Management LLC bought a new position in Krystal Biotech during the third quarter worth $828,000. GK Wealth Management LLC bought a new position in Krystal Biotech during the third quarter worth $59,000. GAMMA Investing LLC increased its position in Krystal Biotech by 10.2% during the third quarter. GAMMA Investing LLC now owns 1,100 shares of the company’s stock worth $366,000 after acquiring an additional 102 shares during the period. Toth Financial Advisory Corp increased its position in Krystal Biotech by 9.5% during the third quarter. Toth Financial Advisory Corp now owns 4,941 shares of the company’s stock worth $1,643,000 after acquiring an additional 430 shares during the period. Finally, Congress Asset Management Co. increased its position in Krystal Biotech by 34.8% during the third quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock worth $17,986,000 after acquiring an additional 13,949 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.